ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation.

AIM The development of chemoradiation - the concurrent administration of chemotherapy and radiotherapy - has led to significant improvements in local tumor control and survival. However, it is limited by its high toxicity. In this study, we report the development of a novel NP (nanoparticle) therapeutic, ChemoRad NP, which can deliver biologically targeted chemoradiation. METHOD A biodegradable and biocompatible lipid-polymer hybrid NP that is capable of delivering both chemotherapy and radiotherapy was formulated. RESULTS Using docetaxel, indium(111) and yttrium(90) as model drugs, we demonstrated that the ChemoRad NP can encapsulate chemotherapeutics (up to 9% of NP weight) and radiotherapeutics (100 mCi of radioisotope per gram of NP) efficiently and deliver both effectively. Using prostate cancer as a disease model, we demonstrated the targeted delivery of ChemoRad NPs and the higher therapeutic efficacy of ChemoRad NPs. CONCLUSION We believe that the ChemoRad NP represents a new class of therapeutics that holds great potential to improve cancer treatment.

[1]  Warren C W Chan,et al.  Mediating tumor targeting efficiency of nanoparticles through design. , 2009, Nano letters.

[2]  Robert Langer,et al.  Superparamagnetic Iron Oxide Nanoparticle-Aptamer Bioconjugates for Combined Prostate Cancer Imaging and Therapy , 2011 .

[3]  Robert Langer,et al.  Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform. , 2008, ACS nano.

[4]  David J Brayden,et al.  Advances in PEGylation of important biotech molecules: delivery aspects. , 2008, Expert opinion on drug delivery.

[5]  Robert Langer,et al.  Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. , 2007, Nano letters.

[6]  Omid C Farokhzad,et al.  Co‐Delivery of Hydrophobic and Hydrophilic Drugs from Nanoparticle–Aptamer Bioconjugates , 2007, ChemMedChem.

[7]  S. Feng,et al.  Poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles prepared by high pressure homogenization for paclitaxel chemotherapy. , 2007, International journal of pharmaceutics.

[8]  Joseph K Salama,et al.  The concurrent chemoradiation paradigm—general principles , 2007, Nature Clinical Practice Oncology.

[9]  Robert Langer,et al.  An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. , 2006, Angewandte Chemie.

[10]  U. Nielsen,et al.  Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.

[11]  J. Richie,et al.  Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[12]  R. Macklis,et al.  Review of clinical radioimmunotherapy , 2006, Expert review of anticancer therapy.

[13]  Stephen J Mather,et al.  Conjugation of chelating agents to proteins and radiolabeling with trivalent metallic isotopes , 2006, Nature Protocols.

[14]  R. Langer,et al.  Poly(Ethylene Oxide)-Modified Poly(β-Amino Ester) Nanoparticles as a pH-Sensitive System for Tumor-Targeted Delivery of Hydrophobic Drugs: Part 2. In Vivo Distribution and Tumor Localization Studies , 2005, Pharmaceutical Research.

[15]  Tae Gwan Park,et al.  Target-specific cellular uptake of PLGA nanoparticles coated with poly(L-lysine)-poly(ethylene glycol)-folate conjugate. , 2005, Langmuir : the ACS journal of surfaces and colloids.

[16]  Omid C. Farokhzad,et al.  Nanoparticle-Aptamer Bioconjugates , 2004, Cancer Research.

[17]  Russell J Mumper,et al.  Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[18]  Xiaowei Liu,et al.  3D absorbed dose calculations based on SPECT: evaluation for 111-In/90-Y therapy using Monte Carlo simulations. , 2003, Cancer biotherapy & radiopharmaceuticals.

[19]  D. S. Coffey,et al.  Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. , 2002, Cancer research.

[20]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[21]  I. Bernstein,et al.  Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. , 1996, Cancer research.

[22]  Y. Barenholz,et al.  Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. , 1991, British Journal of Cancer.

[23]  K. Bhargava,et al.  Labeling of monoclonal antibodies with radionuclides. , 1989, Seminars in nuclear medicine.

[24]  R. New,et al.  REDUCTION IN TOXICITY OF DOXORUBICIN BY LIPOSOMAL ENTRAPMENT , 1987, The Lancet.